163 related articles for article (PubMed ID: 21620697)
21. Nitroarylmethylcarbamate prodrugs of doxorubicin for use with nitroreductase gene-directed enzyme prodrug therapy.
Hay MP; Wilson WR; Denny WA
Bioorg Med Chem; 2005 Jun; 13(12):4043-55. PubMed ID: 15911317
[TBL] [Abstract][Full Text] [Related]
22. Nitrobenzocyclophosphamides as potential prodrugs for bioreductive activation: synthesis, stability, enzymatic reduction, and antiproliferative activity in cell culture.
Li Z; Han J; Jiang Y; Browne P; Knox RJ; Hu L
Bioorg Med Chem; 2003 Sep; 11(19):4171-8. PubMed ID: 12951148
[TBL] [Abstract][Full Text] [Related]
23. Creation and screening of a multi-family bacterial oxidoreductase library to discover novel nitroreductases that efficiently activate the bioreductive prodrugs CB1954 and PR-104A.
Prosser GA; Copp JN; Mowday AM; Guise CP; Syddall SP; Williams EM; Horvat CN; Swe PM; Ashoorzadeh A; Denny WA; Smaill JB; Patterson AV; Ackerley DF
Biochem Pharmacol; 2013 Apr; 85(8):1091-103. PubMed ID: 23399641
[TBL] [Abstract][Full Text] [Related]
24. Nitroreductase-based GDEPT.
Denny WA
Curr Pharm Des; 2002; 8(15):1349-61. PubMed ID: 12052212
[TBL] [Abstract][Full Text] [Related]
25. E. coli nitroreductase/CB1954 gene-directed enzyme prodrug therapy: role of arylamine N-acetlytransferase 2.
Mitchell DJ; Minchin RF
Cancer Gene Ther; 2008 Nov; 15(11):758-64. PubMed ID: 18600257
[TBL] [Abstract][Full Text] [Related]
26. Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT).
Springer CJ; Dowell R; Burke PJ; Hadley E; Davis DH; Blakey DC; Melton RG; Niculescu-Duvaz I
J Med Chem; 1995 Dec; 38(26):5051-65. PubMed ID: 8544182
[TBL] [Abstract][Full Text] [Related]
27. Hypoxia-selective antitumor agents. 12. Nitrobenzyl quaternary salts as bioreductive prodrugs of the alkylating agent mechlorethamine.
Tercel M; Wilson WR; Anderson RF; Denny WA
J Med Chem; 1996 Mar; 39(5):1084-94. PubMed ID: 8676343
[TBL] [Abstract][Full Text] [Related]
28. Synthesis of novel androgen-linked phosphoramide mustard prodrugs and growth-inhibitory activity in human breast cancer cells.
Roth T; Tang W; Eisenbrand G
Anticancer Drug Des; 1995 Dec; 10(8):655-66. PubMed ID: 8595124
[TBL] [Abstract][Full Text] [Related]
29. Nitroimidazole-based "extruded mustards' designed as reductively activated hypoxia-selective cytotoxins.
Hay MP; Denny WA; Wilson WR
Anticancer Drug Des; 1996 Jul; 11(5):383-402. PubMed ID: 8765531
[TBL] [Abstract][Full Text] [Related]
30. An essential type I nitroreductase from Leishmania major can be used to activate leishmanicidal prodrugs.
Voak AA; Gobalakrishnapillai V; Seifert K; Balczo E; Hu L; Hall BS; Wilkinson SR
J Biol Chem; 2013 Oct; 288(40):28466-76. PubMed ID: 23946481
[TBL] [Abstract][Full Text] [Related]
31. Synthesis of ester prodrugs of 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-2,6-diaminopurine (HPMPDAP) as anti-poxvirus agents.
Krecmerová M; Holý A; Andrei G; Pomeisl K; Tichý T; Brehová P; Masojídková M; Dracínský M; Pohl R; Laflamme G; Naesens L; Hui H; Cihlar T; Neyts J; De Clercq E; Balzarini J; Snoeck R
J Med Chem; 2010 Oct; 53(19):6825-37. PubMed ID: 20809641
[TBL] [Abstract][Full Text] [Related]
32. The synthesis of 2-nitroaryl-1,2,3,4-tetrahydroisoquinolines, nitro-substituted 5,6-dihydrobenzimidazo[2,1-a]isoquinoline N-oxides and related heterocycles as potential bioreducible substrates for the enzymes NAD(P)H: quinone oxidoreductase 1 and E. coli nitroreductase.
Burke PJ; Wong LC; Jenkins TC; Knox RJ; Stanforth SP
Bioorg Med Chem Lett; 2011 Dec; 21(24):7447-50. PubMed ID: 22074961
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis and evaluation of targeted hypoxia-activated prodrugs applied to chondrosarcoma chemotherapy.
Gerard Y; Voissière A; Peyrode C; Galmier MJ; Maubert E; Ghedira D; Tarrit S; Gaumet V; Canitrot D; Miot-Noirault E; Chezal JM; Weber V
Bioorg Chem; 2020 May; 98():103747. PubMed ID: 32208207
[TBL] [Abstract][Full Text] [Related]
34. Self-immolative nitrogen mustard prodrugs for suicide gene therapy.
Niculescu-Duvaz D; Niculescu-Duvaz I; Friedlos F; Martin J; Spooner R; Davies L; Marais R; Springer CJ
J Med Chem; 1998 Dec; 41(26):5297-309. PubMed ID: 9857097
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and cytotoxic activity of a glucuronylated prodrug of nornitrogen mustard.
Papot S; Combaud D; Bosslet K; Gerken M; Czech J; Gesson JP
Bioorg Med Chem Lett; 2000 Aug; 10(16):1835-7. PubMed ID: 10969980
[TBL] [Abstract][Full Text] [Related]
36. Sulfonyl-containing aldophosphamide analogues as novel anticancer prodrugs targeted against cyclophosphamide-resistant tumor cell lines.
Jain M; Fan J; Baturay NZ; Kwon CH
J Med Chem; 2004 Jul; 47(15):3843-52. PubMed ID: 15239662
[TBL] [Abstract][Full Text] [Related]
37. Steady-state and stopped-flow kinetic studies of three Escherichia coli NfsB mutants with enhanced activity for the prodrug CB1954.
Jarrom D; Jaberipour M; Guise CP; Daff S; White SA; Searle PF; Hyde EI
Biochemistry; 2009 Aug; 48(32):7665-72. PubMed ID: 19580253
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and biological evaluation of cyclic nitrogen mustards based on carnitine framework.
Leiris S; Lucas M; Dupuy d'Angeac A; Morère A
Eur J Med Chem; 2010 Sep; 45(9):4140-8. PubMed ID: 20615582
[TBL] [Abstract][Full Text] [Related]
39. E. coli nitroreductase/CB1954: in vitro studies into a potential system for feline cancer gene therapy.
Blackwood L; O'Shaughnessy PJ; Reid SW; Argyle DJ
Vet J; 2001 May; 161(3):269-79. PubMed ID: 11352484
[TBL] [Abstract][Full Text] [Related]
40. Testing double mutants of the enzyme nitroreductase for enhanced cell sensitisation to prodrugs: effects of combining beneficial single mutations.
Jaberipour M; Vass SO; Guise CP; Grove JI; Knox RJ; Hu L; Hyde EI; Searle PF
Biochem Pharmacol; 2010 Jan; 79(2):102-11. PubMed ID: 19665450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]